Biosimilar Newsletter Archive
-
03.07.24 -- Cardinal Health Report Examines Milestone Year In Biosimilars
3/7/2024
03/07/24 Biosimilar Development Newsletter
-
03.03.24 -- Samsung Bioepis Initiates Ph. 1 For Keytruda Biosimilar
3/3/2024
03/03/24 Biosimilar Development Newsletter
-
02.29.24 -- Samsung Bioepis Initiates Ph. 1 For Keytruda Biosimilar
2/29/2024
02/29/24 Biosimilar Development Newsletter
-
02.22.24 -- Analyzing & Kickstarting Organizational Quality Maturity
2/22/2024
02/22/24 Biosimilar Development Newsletter
-
02.15.24 -- How To Develop Innovative, Intuitive, Patient Friendly Drug Delivery Devices
2/15/2024
02/15/24 Biosimilar Development Newsletter
-
02.15.24 -- When Does Continuous Manufacturing Make Sense?
2/15/2024
02/15/24 Biosimilar Development Newsletter
-
02.08.24 -- Protein L Affinity Resin Is Ready To Move To Manufacturing
2/8/2024
02/08/24 Biosimilar Development Newsletter
-
02.01.24 -- A New Year's Resolution Suggestion For The FDA
2/1/2024
02/01/24 Biosimilar Development Newsletter
-
01.31.24 -- The Business Of Biotech: Leaders In Emerging Technologies
1/31/2024
01/31/24 Biosimilar Development Newsletter
-
01.28.24 -- Samsung Bioepis Releases Q124 US Biosimilars Report
1/28/2024
01/28/24
This website uses cookies to ensure you get the best experience on our website. Learn more